Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65 RNA-LP + tumor mRNA RNA-LP
- Development stage
- Unknown
- Lead developer
- University of Florida
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
This is an investigational personalized RNA-lipid particle (RNA-LP) vaccine system developed by the University of Florida for the treatment of recurrent high-grade glioma and recurrent or unresectable osteosarcoma in pediatric and young adult patients. The vaccine regimen consists of two components: DP1, an off-the-shelf vaccine containing mRNA encoding the cytomegalovirus (CMV) phosphoprotein 65 (pp65) antigen used to prime the immune response, and DP2, a patient-specific vaccine containing both pp65 mRNA and personalized tumor-derived mRNA. These mRNAs are encapsulated in DOTAP-based cationic lipid particles. Administered intravenously, the RNA-LPs are designed to localize to lymphoid tissues, transfect and activate antigen-presenting cells (APCs), and induce potent antigen-specific T-cell immunity to overcome the immunosuppressive environment of high-grade brain and bone tumors.
- Other names
- pp65 messenger RNA-lipid particles + tumor messenger RNA-lipid particlesRNA-LP vaccineRNA PRIME vaccine
02
Targets
MAGEA8 (Melanoma-associated antigen 8)pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on pp65 RNA-LP + tumor mRNA RNA-LP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65 RNA-LP + tumor mRNA RNA-LP.